BusinessJun 12, 2024
AstraZeneca’s Prescription For Growth Includes Cancer Treatments, Weightloss Drugs, and a New $80B Sales Target
Biopharma Strategy
Rhea Lobo
Discover
Savior of lives, pioneer of solutions, and an alchemist that conjures up profits — AstraZeneca is an icon, a legend, and the moment in the pharmaceutical industry. Britain’s most valuable company is on a mission to nearly double its revenues to $80B by 2030, but getting there won’t be easy.
Astral (revenue) projections: AstraZeneca’s stock keeps reaching new all-time highs, achieving over 100% growth in the past five years (with total returns even higher when factoring in its 3% dividend yield) — outpacing the S&P 500’s 88% return. AstraZeneca has achieved five consecutive years of revenue growth, fueled by successful drugs like Farxiga for diabetes and Tagrisso for cancer treatment. But reaching their new target hinges on the success of upcoming key late-stage trials expected to generate $20B in revenue by 2030.
AstraZeneca remains competitive due to strong research and development investments, a diversified product portfolio, and deep pockets. In recent years, the company has invested billions into large acquisitions and partnerships — with little signs of slowing.
Trouble in pharmaland: Regulatory pressures and geopolitical tensions risk putting a stop to AstraZeneca’s plans. A US federal court ruling now mandates pharmaceutical companies negotiate drug prices with Medicare — potentially slashing profits by 25-60%. The company is also developing a separate supply chain in China, hoping that Chinese drug sales will help achieve its revenue target and ease US-China tensions. Fortunately for investors, AstraZeneca reached its $45B revenue target last year — a goal initially set in 2014. Now, it’ll need to do it all over again.
